US 12,083,326 B2
Drug delivery device with restricted cap replacement
Stefan Wendland, Frankfurt am Main (DE); and Michael Harms, Frankfurt am Main (DE)
Assigned to Sanofi-Aventis Deutschland GMBH, Frankfurt am Main (DE)
Filed by Sanofi-Aventis Deutschland GMBH, Frankfurt am Main (DE)
Filed on Nov. 16, 2021, as Appl. No. 17/527,748.
Application 17/527,748 is a continuation of application No. 16/322,362, granted, now 11,185,640, previously published as PCT/EP2017/069134, filed on Jul. 28, 2017.
Claims priority of application No. 16182303 (EP), filed on Aug. 2, 2016.
Prior Publication US 2022/0072239 A1, Mar. 10, 2022
Int. Cl. A61M 5/32 (2006.01); A61M 5/31 (2006.01); A61M 5/50 (2006.01)
CPC A61M 5/3213 (2013.01) [A61M 5/3202 (2013.01); A61M 5/3219 (2013.01); A61M 5/50 (2013.01); A61M 2005/312 (2013.01); A61M 2005/3217 (2013.01); A61M 2205/273 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A drug delivery device comprising:
a housing configured to receive a needle; and
a cap removably attached to the housing to cover the needle;
wherein the cap comprises a locking member having a proximal end and a distal end, the locking member connected to the cap at the distal end of the locking member and extending proximally from a wall of the cap, the locking member comprising a resiliently biased member that is held in a deflected position when the cap is fully connected to the drug delivery device, and wherein the locking member is movable relative to the wall of the cap to a locking position when the cap is removed from the housing, the locking member in the locking position being configured to prevent the cap from being attached to the housing.